Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform

Genentech is adding a new trial using Syndax’s lead drug entinostat to its platform for testing new drug combinations with its PD-L1 drug Tecentriq (atezolizumab).

The cancer drug giant set up a program called Morpheus for these combos. Now their researchers will use the combination therapy to treat metastatic HR+, HER2- breast cancer.

Briggs Morrison

This is the second development deal that Syndax $SNDX has put together with Genentech. The first centered on a combination of the biotech’s lead effort with Tecentriq in a Phase Ib/II trial for triple negative breast cancer. The Phase II part of that study is expected to complete enrollment in the first half of this year.

These kinds of add-on approaches to treating cancer have spawned a tidal wave of trials. But in the PD-1/L1 world the two leaders in the field — Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo — have overshadowed atezo.

Syndax CEO Briggs Morrison, though, has close ties with Genentech and offered a thumbs up on the deal.

While checkpoint inhibitors have shown initial promise in triple-negative breast cancer, there is a clear need to augment the effectiveness of such therapies in the setting of HR+, HER2- breast cancer.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->